Health Care • Other Pharmaceuticals
$1.83 ▲ +0.06
(+3.10%)
MKT CAP: $54.4M • VOL: 3.9K
52W L $1 52W H $3
ROARABLE / RQD
D- • 41/100
PIOTROSKI
4 / 9
ESYN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $866.9K | $1.3M | $1.2K |
| YoY Revenue Growth % | -30.8% | +105776.4% | — |
| Gross Profit | $459.7K | $601.9K | — |
| Gross Margin % | 53.0% | 48.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$2.6M | -$2.7M | -$1.1M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$1.8M | -$1.8M | -$2.6M |
| Capital Expenditures (CapEx) | $19.5K | $30.4K | — |
| Free Cash Flow (FCF) | -$1.8M | -$1.8M | -$2.6M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $2.1M | $4.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.6M | $2.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ESYN.